OCX Stock Overview
A precision diagnostics company in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
OncoCyte Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.94 |
| 52 Week High | US$4.75 |
| 52 Week Low | US$1.92 |
| Beta | 0.98 |
| 1 Month Change | -21.39% |
| 3 Month Change | 33.64% |
| 1 Year Change | 6.91% |
| 3 Year Change | -87.95% |
| 5 Year Change | -93.47% |
| Change since IPO | -97.65% |
Recent News & Updates
Recent updates
GraftAssure Assay Submissions Will Unlock Transplant Center Opportunities
Apr 13 Strategic partnerships and anticipated regulatory approvals are poised to significantly expand OncoCyte's market reach, boosting revenue and supporting scalability.Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?
Oct 28
Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test
Aug 30Revisiting OncoCyte Corp.
May 04Shareholder Returns
| OCX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.9% | 8.1% | 8.4% |
| 1Y | 6.9% | -7.2% | 5.9% |
Return vs Industry: OCX exceeded the US Biotechs industry which returned -8% over the past year.
Return vs Market: OCX exceeded the US Market which returned 5.9% over the past year.
Price Volatility
| OCX volatility | |
|---|---|
| OCX Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: OCX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OCX's weekly volatility (11%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 48 | Josh Riggs | www.oncocyte.com |
OncoCyte Corporation, a precision diagnostics company in the United States and internationally. It develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. The company is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
OncoCyte Corporation Fundamentals Summary
| OCX fundamental statistics | |
|---|---|
| Market cap | US$81.36m |
| Earnings (TTM) | -US$60.93m |
| Revenue (TTM) | US$1.88m |
44.7x
P/S Ratio-1.4x
P/E RatioIs OCX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCX income statement (TTM) | |
|---|---|
| Revenue | US$1.88m |
| Cost of Revenue | US$1.05m |
| Gross Profit | US$828.00k |
| Other Expenses | US$61.75m |
| Earnings | -US$60.93m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.13 |
| Gross Margin | 44.02% |
| Net Profit Margin | -3,239.02% |
| Debt/Equity Ratio | 0% |
How did OCX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/15 11:27 |
| End of Day Share Price | 2025/04/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OncoCyte Corporation is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Paul Knight | Janney Montgomery Scott LLC |
| Paul Knight | KeyBanc Capital Markets Inc. |